Effect of cisapride on relapse of reflux oesophagitis, healed with an antisecretory drug.
Maintenance treatment with cisapride was evaluated in 298 patients in whom reflux oesophagitis had been healed with antisecretory drugs. Initially, 34% of the patients had grade-I oesophagitis, 33% had grade II, and 33% had grade III. The patients were treated with 20 mg cisapride twice daily or placebo for 6 months or until endoscopic relapse was shown if this occurred earlier. Survival analysis showed that cisapride significantly prolonged the time to endoscopic relapse in grade-I patients (P = 0.02). The intergroup difference in symptomatic relapse in all patients was also significant (P = 0.010). The effect of cisapride was less clearcut in grade II or III, and/or in patients healed with omeprazole. Factors associated with early relapse were placebo therapy, prior omeprazole therapy, duration of pre-trial symptomatic period, and initial endoscopic severity grade. Adverse experiences were limited; diarrhoea was reported by 9% of the cisapride patients.
Tytgat
G N
GN
Dept. of Gastroenterology and Hepatology, Academic Medical Centre, Amsterdam, The Netherlands.
Anker Hansen
O J
OJ
Carling
L
L
de Groot
G H
GH
Geldof
H
H
Glise
H
H
Efskind
P
P
Elsborg
L
L
Karvonen
A L
AL
Ohlin
B
B
D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D020117:Cisapride; D004311:Double-Blind Method; D004942:Esophagitis, Peptic / Q000188:drug therapy* / Q000453:epidemiology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000627:therapeutic use; D010880:Piperidines / Q000627:therapeutic use*; D012008:Recurrence; D012702:Serotonin Antagonists / Q000627:therapeutic use*; D016019:Survival Analysis
D000897:Anti-Ulcer Agents; D010880:Piperidines; D012702:Serotonin Antagonists; D009853:Omeprazole; D020117:Cisapride